

Approved



Nigeria
Country Operational Plan
FY 2016



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		719,541		719,541	0	719,541
USAID		148,799,251		148,799,251	124,943,529	273,742,780
DOD		7,732,490		7,732,490	6,337,063	14,069,553
HHS/CDC	1,962,500	75,532,594		77,495,094	42,800,830	120,295,924
State/AF		0		0	300,000	300,000
Total	1,962,500	232,783,876	0	234,746,376	174,381,422	409,127,798

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency					On Hold Amount	Total
	State	DOD	HHS/CDC	State/AF	USAID		
HBHC		1,248,331	24,090,157		1,866,738	0	27,205,226
HKID		0	15,474,306	0	21,906,618	0	37,380,924
HLAB		46,234	61,564		10,326	0	118,124
HMBL		0	8,465		424,023	0	432,488
HMIN		0	769		153,631	0	154,400
HTXD		44,032			58,666,947	0	58,710,979
HTXS		499,330	20,004,015		14,268,712	0	34,772,057
HVAB			769		0	0	769
HVCT		4,403	12,827		10,043,664	0	10,060,894
HVMS	719,541	2,582,305	1,188,280		7,149,884	0	11,640,010
HVOP		638,913	8,465	0	12,994,282	0	13,641,660
HVSI		784,300	3,048,329	0	5,351,860	0	9,184,489
HVTB		242,153	3,174,011		981,575	0	4,397,739

Approved



MTCT		1,297,704	4,488,242		9,697,028	0	15,482,974
OHSS		10,236	10,773		2,991,380	0	3,012,389
PDCS		330,146	3,682,339		1,566,565	0	5,579,050
PDTX		4,403	2,241,783		726,018	0	2,972,204
	719,541	7,732,490	77,495,094	0	148,799,251	0	234,746,376



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	27,037,731	0
HKID	37,128,400	0
HVTB	4,148,614	0
PDCS	5,449,270	0
Total Technical Area Planned Funding:	73,764,015	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	0	0
HVSI	8,198,599	0
OHSS	2,596,332	0
Total Technical Area Planned Funding:	10,794,931	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
HMBL	424,023	0
HMIN	153,631	0
HVAB	0	
HVCT	9,958,521	0
HVOP	13,548,371	0
MTCT	15,331,399	0
Total Technical Area Planned Funding:	39,415,945	0

Approved



Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXD	58,604,982	0
HTXS	34,394,933	0
PDTX	2,803,394	0
Total Technical Area Planned Funding:	95,803,309	0



Technical Area Summary Indicators and Targets

Indicator Number	Label	2017
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,739,618
	Number of new ANC and L&D clients	1,834,319
	By: Known positives at entry	39,702
	By: Number of new positives identified	26,608
	Sum of Positives Status disaggregates	66,310
	Required only for DREAMS Countries - By Number of new positives: <15	
	Required only for DREAMS Countries - By Number of new positives: 15-19	
	Required only for DREAMS Countries - By Number of new positives: 20-24	
	Required only for DREAMS Countries - By Number of known positives: <15	
	Required only for DREAMS Countries - By Number of known	



	positives: 15-19	
	Required only for DREAMS Countries - By Number of known positives: 20-24	
	Required only for DREAMS Countries - Denominator: <15	
	Required only for DREAMS Countries - Denominator: <15-19	
	Required only for DREAMS Countries - Denominator: 20-24	
	Required only for DREAMS Countries - Denominator: 25-49	
	Required only for DREAMS Countries - Denominator: 50+	
	Required only for DREAMS Countries - By Number of known positives: 25-49	
	Required only for DREAMS Countries - By Number of known positives: 50+	
	Required only for DREAMS Countries - By Number of new positives: 25-49	
	Required only for DREAMS Countries - By Number of new positives: 50+	
	By Age (DREAMS SNU's ONLY): <15	
	By Age (DREAMS SNU's ONLY): 15-19	
	By Age (DREAMS SNU's ONLY): 20-24	
	By Age (DREAMS SNU's ONLY): 25-49	



	By Age (DREAMS SNU's ONLY): 50+	
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,739,618
	New on ART	29,130
	Already on ART at beginning of current pregnancy	16,948
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	218,863
	Total estimated number of key population in the catchment area	269,670
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level	19,461



	HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	33,932
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	161,231
	By key population type: Males who	3,412



	inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	827
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	4,996
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	12,478
	By key population type: Transgender who are sex workers (Denominator: Total estimated	



	number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	246,931
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	3,454
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	1,811
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report	



	period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	6,484,137
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	281
	Age/sex: 15-19 Male	116
	Age/sex: 20-24 Male	0
	Age/sex: 25-49 Male	0
	Age/sex: 50+ Male	0
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	281
	Age/sex: 15-19 Female	116
	Age/sex: 20-24 Female	0
	Age/sex: 25-49 Female	0
	Age/sex: 50+ Female	0
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
Test Result by Age and Sex: Positive: 20-24 Female		



	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	250,679
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,018,148
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	286,848
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,889,558



Test Result by Aggregated Age and Sex: Negative <15 Male	3
Test Result by Aggregated Age and Sex: Negative 15+ Male	104
Test Result by Aggregated Age and Sex: Negative <15 Female	4
Test Result by Aggregated Age and Sex: Negative 15+ Female	919
Test Result by Aggregated Age and Sex: Positive <15 Male	6,479
Test Result by Aggregated Age and Sex: Positive 15+ Male	94,786
Test Result by Aggregated Age and Sex: Positive <15 Female	8,039
Test Result by Aggregated Age and Sex: Positive 15+ Female	101,840
Test Result by Age: Positive: <1	
Test Result by Age: Positive: 1-9	
Age/sex: <1	74
Age/sex: 1-9	882
Service Delivery Point (Community): Index testing	37,701
Service Delivery Point (Community): Homebased testing	33,452
Service Delivery Point (Community): Mobile testing	810,886
Service Delivery Point (Community): Other	25,015
Service Delivery Point (Community) by Age: <15 index testing	
Service Delivery Point (Community) by Age: 15+ index testing	
Service Delivery Point (Community) by Age: <15 homebased testing	



	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	8,240
	Service Delivery Point (Facility): Outpatient	2,352,787
	Service Delivery Point (Facility): Pediatric	530,275
	Service Delivery Point (Facility): Malnutrition facilities	4,140
	Service Delivery Point (Facility): Other PITC	11,020
	Service Delivery Point (Facility): VCT	880,198
	Service Delivery Point (Facility): VMMC	983
	Service Delivery Point (Facility): PMTCT	1,706,859
	Service Delivery Point (Facility): TB Clinics	93,865
	Service Delivery Point (Facility): Index testing	7,694
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	



	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatroc	
	Service Delivery Point (Facility) by Age: >15 Pediatroc	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	



	Service Delivery Point (Facility) by Age: >15 Index testing	
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	44,000
	Total number of registered new and relapsed TB cases, during the reporting period.	49,020
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with	



	documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,089
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	23,731
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	860
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	18,779
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV Negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 10-14 (Denominator: Total number of	



	registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 50+	



	(Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
GEND_GBV_DSD	Number of people receiving post-GBV care	31,843
	Age/Sex: <10 Male	33
	Age/Sex: 10-14 Male	560
	Age/Sex: 15-17 Male	
	Age/Sex: 18-19 Male	
	Age/Sex: 20-24 Male	22
	Age/Sex: 25-49 Male	5,172
	Age/Sex: 50+ Male	0
	Age/Sex: <10 Female	31
	Age/Sex: 10-14 Female	498
	Age/Sex: 15-17 Female	
	Age/Sex: 18-19 Female	
	Age/Sex: 20-24 Female	136
Age/Sex: 25-49 Female	11,629	



	Age/Sex: 50+ Female	0
	Sum of Age/Sex Disaggregates	1,122
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	10,439
	By type of service: Sexual Violence (Post-Rape Care)	21,345
	By PEP service provision (related to sexual violence services provided)	17,601
	Age/Sex: 15-19 Female	31
	Age/Sex: 15-19 male	27
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,129,206
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By: Age/sex: Male 18-24	
	By: Age/sex: Male 25+	
	Age/Sex: 18+ Male	135,371
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By: Age/sex: 18-24 Female	
	By: Age/sex: 25+ Female	
	Age/Sex: 18+ Female	187,237
	Sum of Age/Sex disaggregates	322,608
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	



	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	



	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	



	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS	



	countries - By service, age and sex: Economic Strengthening Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	



	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	



	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	
	Program Completion: Active	
	Program Completion: Graduation	
	Program Completion: Transferred	
	Program Completion: Exited without graduation	
	By Aggregated Age/Sex: <18 Male	377,837
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	428,762
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	
	Required only for DREAMS	



	countries - By service, age and sex: Social Protection Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	7,502
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	9,009
	Age/Sex: >1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	



	<p>Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during</p>	



	the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	138
	Aggregated Age/Sex: Male 15+	3,467



	(Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	158
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3,723
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of	



	registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented	



	HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB	



	treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	1,029,111
	Screened for TB by Age/Sex:<15 Male	33,970
	Screened for TB by Age/Sex: 15+ Male	271,068
	Screened for TB by Age/Sex:<15 Female	23,994
	Screened for TB by Age/Sex: 15+ Female	700,080



	Screen Result: Screened Positive for TB	23,367
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	21,130
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	9
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	18,919
	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	21,472
	By infants who received their first virologic HIV test between 2 and 12 months of age	24,594



	Sum of Infant Age disaggregates	46,066
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	453
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	1,229
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	832,599
	Age/Sex: 15-19 Male	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	26,227
	Aggregated Age/Sex: 15+ Male	236,376
	Aggregated Age/Sex: <15 Female	27,284
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	542,711
	Sum of Aggregated Age/Sex <15	53,511
	Sum of Aggregated Age/Sex 15+	779,087
	Sum of Aggregated Age/Sex	832,598



	disaggregates	
	Age/Sex: <1	0
	Age/Sex: <1-9	0
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	168,119
	By Age/Sex: <1	0
	By Age/Sex: 1-9	0
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1	



	Male	
	Aggregated Grouping by Age/Sex: <15 Male	5,776
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	73,066
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	6,574
	Aggregated Grouping by Age/Sex: 15+ Female	82,691
	Sum of Aggregated Age/Sex disaggregates	168,107
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	749,428
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical	838,606



	record and /or laboratory records in the past 12 months.	
	Numerator: Indication: Routine	595,802
	Numerator: Indication: Targeted	148,963
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	



	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	



	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Indication: Routine	666,571
	Denominator: Indication: Targeted	167,202
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	



	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	



	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex: <15 Male	17,545
	Numerator Aggregated Age/Sex: 15+ Male	214,636
	Numerator Aggregated Age/Sex: <15 Female	17,084
	Numerator Aggregated Age/Sex: 15+ Female	500,162
	Denominator Aggregated Age/Sex: <15 Male	19,419
	Denominator Aggregated Age/Sex: 15+ Male	240,111
	Denominator Aggregated Age/Sex: <15 Female	18,971
	Denominator Aggregated Age/Sex: 15+ Female	559,946
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a



	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	231,371
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	272,722
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator:	



	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who	



	initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	



	those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated	



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	



	those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,171
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	64,849
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,885
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	156,467
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,082



	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	76,525
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,756
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	184,359
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	288
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	286



	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	265
	CD4: Number of laboratories that perform this testing	237
	CD4: Number of laboratories that participate in this PT program	237
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	216
	Early infant diagnostics: Number of laboratories that perform this testing	14
	Early infant diagnostics: Number of laboratories that participate in this PT program	14
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	14
	HIV viral load: Number of laboratories that perform this testing	14
	HIV viral load: Number of laboratories that participate in this PT program	14
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	14
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	22
	TB diagnostics (AFB microscopy):	22



	Number of laboratories that participate in this PT program	
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	19
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	11
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	11
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	9
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	680
	By Graduates: Doctors	
	By Graduates: Nurses	240
	By Graduates: Midwives	200

Approved



	By Graduates: Social service workers	
	By Graduates: Laboratory professionals	
	By Graduates: Other	240
	Sum of Graduates disaggreagtes	680



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
10004	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
10015	National Blood Transfusion Service of Nigeria	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
10019	Safe Blood for Africa Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12831	African Field Epidemiology Network	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,793,750



13713	Medical Laboratories Science Council of Nigeria	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14055	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	0
14064	IntraHealth International, Inc	NGO	U.S. Agency for International Development	GHP-State	0
14169	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	0
14298	Deloitte Consulting Limited	Private Contractor	U.S. Agency for International Development	GHP-State	0
14302	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	0
14446	The Mitchell Group	Private Contractor	U.S. Agency for International Development	GHP-State	0
14505	FHI 360	NGO	U.S. Agency for International Development	GHP-State	10,205,189
14664	Heartland Alliance for Human Needs and Human Rights	NGO	U.S. Agency for International Development	GHP-State	10,236,990
14666	TBD	TBD	Redacted	Redacted	Redacted
14768	Partnership for Supply Chain	Private Contractor	U.S. Agency for International	GHP-State	0



	Management		Development		
16797	Pathfinder International	NGO	U.S. Agency for International Development	GHP-State	0
16827	Center for Integrated Health Programs	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
16828	AIDS Prevention Initiative in Nigeria, LTD	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
16838	University of Maryland Baltimore	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	400,000
16839	Institute of Human Virology, Nigeria	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
16848	Catholic Caritas Foundation of Nigeria (CCFN)	Implementing Agency	U.S. Department of Health and Human Services/Centers	GHP-State	6,428,971



			for Disease Control and Prevention		
16850	AIDS Prevention Initiative in Nigeria, LTD	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	15,933,832
16852	African Society for Laboratory Medicine	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
16853	Center for Clinical Care and Clinical Research Ltd	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	700,000
16854	Center for Clinical Care and Clinical Research Ltd	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,906,228
16855	Center for Integrated Health Programs	NGO	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	21,567,887



			Control and Prevention		
16871	Institute of Human Virology, Nigeria	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	20,099,773
17195	Health Initiatives for Safety and Stability in Africa	NGO	U.S. Department of Defense	GHP-State	0
17727	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	0
17728	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	4,989,384
17729	Save the Children US	NGO	U.S. Agency for International Development	GHP-State	2,529,518
17733	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	0
17734	KNCV Tuberculosis Foundation	NGO	U.S. Agency for International Development	GHP-State	1,816
17735	Society for Family Health-Nigeria	Private Contractor	U.S. Agency for International Development	GHP-State	954,963
17737	Health Initiatives for Safety and Stability in Africa	NGO	U.S. Agency for International Development	GHP-State	1,882,163
17739	United Nations Children's Fund	Multi-lateral Agency	U.S. Agency for International	GHP-State	0



			Development		
17742	Friends for Global Health Initiative in Nigeria	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,523,622
17743	Pro-Health International	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	869,142
17744	Excellence Community Education Welfare Scheme (ECEWS)	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	950,622
17745	Achieving Health Nigeria Initiative	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	358,767
17747	Henry Jackson Foundation	Private Contractor	U.S. Department of Defense	GHP-State	4,692,362
17749	TBD	TBD	Redacted	Redacted	Redacted
18010	Association for Reproductive and Family Health	NGO	U.S. Agency for International Development	GHP-State	3,107,796



18070	TBD	TBD	Redacted	Redacted	Redacted
18075	Widows and Orphans Empowerment Organization	NGO	U.S. Agency for International Development	GHP-State	1,970,862
18076	Dexis Consulting Group	Private Contractor	U.S. Agency for International Development	GHP-State	0
18127	University of North Carolina at Chapel Hill, Carolina Population Center	University	U.S. Agency for International Development	GHP-State	1,700,000
18128	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	3,284,144
18129	TBD	TBD	Redacted	Redacted	Redacted
18438	AFENET CDC HQ	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
18439	TBD	TBD	Redacted	Redacted	Redacted
18441	TBD	TBD	Redacted	Redacted	Redacted
18442	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	97,250,183



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 10004	Mechanism Name: APHL's Partnership with HHS/CDC to assist PEPFAR Build Quality Laboratory Capacity_799
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 350,000	
Total All Funding Sources and Applied Pipeline Amount: 350,000	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	10004		
Mechanism Name:	APHL's Partnership with HHS/CDC to assist PEPFAR Build Quality Laboratory Capacity_799		
Prime Partner Name:	Association of Public Health Laboratories		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10015	Mechanism Name: National Blood Transfusion Service (NBTS)_997
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Blood Transfusion Service of Nigeria	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:
Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	10015		
Mechanism Name:	National Blood Transfusion Service (NBTS)_997		
Prime Partner Name:	National Blood Transfusion Service of Nigeria		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	0	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10019	Mechanism Name: Safe Blood for Africa Foundation
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Safe Blood for Africa Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:
Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	10019		
Mechanism Name:	Safe Blood for Africa Foundation		
Prime Partner Name:	Safe Blood for Africa Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	0	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12831	Mechanism Name: Improving the quality of health service delivery through training support for epidemiology, M&E, survey and laboratory services_431
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Field Epidemiology Network	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,793,750	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,793,750	
Funding Source	Funding Amount
GHP-State	1,793,750

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12831
Mechanism Name:	Improving the quality of health service delivery through training support for epidemiology, M&E, survey and laboratory services_431
Prime Partner Name:	African Field Epidemiology Network



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	1,793,750	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13713	Mechanism Name: Mentoring Laboratories Towards National Accreditation (MELTNA)_090
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Medical Laboratories Science Council of Nigeria	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 13713			
Mechanism Name: Mentoring Laboratories Towards National Accreditation (MELTNA)_090			
Prime Partner Name: Medical Laboratories Science Council of Nigeria			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14055	Mechanism Name: PLAN-Health
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 14055			
Mechanism Name: PLAN-Health			
Prime Partner Name: Management Sciences for Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14064	Mechanism Name: Capacity Plus
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 14064			
Mechanism Name: Capacity Plus			
Prime Partner Name: IntraHealth International, Inc			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14169	Mechanism Name: Health Finance and Governance Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 14169			
Mechanism Name: Health Finance and Governance Project			
Prime Partner Name: Abt Associates			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14298	Mechanism Name: Enhancing Nigerian Capacity for AIDS Prevention
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Deloitte Consulting Limited	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 14298			
Mechanism Name: Enhancing Nigerian Capacity for AIDS Prevention			
Prime Partner Name: Deloitte Consulting Limited			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14302	Mechanism Name: Strengthening High Impact Interventions for and AIDS-free Generation (Aids Free)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	

Approved



Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14302		
Mechanism Name:	Strengthening High Impact Interventions for and AIDS-free Generation		
Prime Partner Name:	(Aids Free) John Snow Inc (JSI)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14446	Mechanism Name: Nigeria Monitoring and Evaluation Management Services (NMEMS II)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: The Mitchell Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14446		
Mechanism Name:	Nigeria Monitoring and Evaluation Management Services (NMEMS II)		
Prime Partner Name:	The Mitchell Group		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14505	Mechanism Name: STRENGTHENING INTERGRATED DELIVERY OF HIV/AIDS SERVICES(SIDHAS)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 10,205,189	
Applied Pipeline Amount: 37,250,124	
Total All Funding Sources and Applied Pipeline Amount: 47,455,313	
Funding Source	Funding Amount
GHP-State	10,205,189

Cross-Cutting Budget Attribution(s)

Human Resources for Health	3,338,800
Food and Nutrition: Commodities	250,000
Economic Strengthening	195,000
Renovation	453,594
Gender: GBV	1,513,627
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: Gender Equality	260,485
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information



Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Education	39,520
Motor Vehicles: Purchased	852,450



Budget Code Information

Mechanism ID:	14505		
Mechanism Name:	STRENGTHENING INTERGRATED DELIVERY OF HIV/AIDS		
Prime Partner Name:	SERVICES(SIDHAS)		
	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	2,982,703	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	2,798,942	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	4,423,544	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	615,645
PMTCT_ART_DSD	New on ART	12,280
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	4,050
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	615,645
PMTCT_STAT_DSD	Number of new ANC and L&D clients	651,040
PMTCT_STAT_DSD	By: Known positives at entry	24,105
PMTCT_STAT_DSD	By: Number of new positives identified	10,641
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	34,746
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,935,315
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	86,140
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	539,850



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	97,110
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,212,215
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	183,250
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	1,752,065
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	1,935,315
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	1,974
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	21,997
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	2,494
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	25,217
HTC_TST_DSD	Age/sex: <1	0
HTC_TST_DSD	Service Delivery Point (Community): Index testing	4,863
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	238,286
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	2,009
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	660,143
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	181,671
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	1,035
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	102
HTC_TST_DSD	Service Delivery Point (Facility): VCT	229,084
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	79
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	582,791
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	24,165
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	2,012
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	13,165
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	14,725
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of	338

	registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7,044
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	268
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5,515
GEND_GBV_DSD	Number of people receiving post-GBV care	2,808
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,174
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,634
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,382
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	88,032
OVC_SERV_DSD	Age/Sex: 18+ Male	43,616
OVC_SERV_DSD	Age/Sex: 18+ Female	43,623
OVC_SERV_DSD	Sum of Age/Sex disaggregates	87,239
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	396
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	397
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,282
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,544
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	47

	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,074
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	52
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,109
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	287,713
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	13,230
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	69,763
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	7,416
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	197,304
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	6,620
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	5,952
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	5,358
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,728
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	14,226
PMTCT_EID_DSD	Sum of Infant Age disaggregates	15,954



PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	116
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	1,013
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	257,214
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	7,472
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	80,994
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	8,170
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	160,578
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	15,642
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	241,572
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	257,214
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	49,008
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1,955
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	21,177
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	2,209
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	23,647
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	48,988
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	231,566
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	257,688
TX_PVLS_DSD	Numerator: Indication: Routine	185,255
TX_PVLS_DSD	Numerator: Indication: Targeted	46,311
TX_PVLS_DSD	Denominator: Indication: Routine	206,151
TX_PVLS_DSD	Denominator: Indication: Targeted	51,537
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	5,021
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	73,119



TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	5,009
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	148,417
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	5,584
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	81,380
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	5,565
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	165,159
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	57,899
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	68,115
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,167
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17,672
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,164
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	37,896
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,373
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	20,777



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,376
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	44,589

Implementing Mechanism Details

Mechanism ID: 14664	Mechanism Name: Integrated MSM Prevention Program
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Heartland Alliance for Human Needs and Human Rights	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 10,236,990	
Applied Pipeline Amount: 71,216	
Total All Funding Sources and Applied Pipeline Amount: 10,308,206	
Funding Source	Funding Amount
GHP-State	10,236,990

Cross-Cutting Budget Attribution(s)

Human Resources for Health	2,800,000
Education	150,000
Key Populations: MSM and TG	150,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions



	for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	200,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: GBV	364,182
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information



Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	1,206,247
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation



Budget Code Information

Mechanism ID:	14664		
Mechanism Name:	Integrated MSM Prevention Program		
Prime Partner Name:	Heartland Alliance for Human Needs and Human Rights		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	579,121	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	9,657,869	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	127,642
KP_PREV_DSD	Total estimated number of key population in the catchment area	156,031
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	30,862



KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	94,493
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,829
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	458
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	8,866
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	144,306
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	1,779
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	1,080
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	97,678
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	52,504
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	13,227



HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	65,731
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	65,731
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	25,576
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	6,432
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	97,649
HTC_TST_DSD	Service Delivery Point (Community): Other	29
GEND_GBV_DSD	Number of people receiving post-GBV care	2,882
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	2,371
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	511
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	257
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	780
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	236
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	544
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	780
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	780
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	922
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	275
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	647
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	922

Implementing Mechanism Details

Mechanism ID: 14666	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 14768	Mechanism Name: SUPPLY CHAIN
----------------------------	-------------------------------------



	MANAGEMENT SYSTEMS
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Partnership for Supply Chain Management	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14768		
Mechanism Name:	SUPPLY CHAIN MANAGEMENT SYSTEMS		
Prime Partner Name:	Partnership for Supply Chain Management		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 16797	Mechanism Name: Evidence To Action for strengthened Family Planning & Health Services for Women & Girls (E2A)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Pathfinder International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16797		
Mechanism Name:	Evidence To Action for strengthened Family Planning & Health Services for Women & Girls (E2A)		
Prime Partner Name:	Pathfinder International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HMBL	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16827	Mechanism Name: Strengthening Skills and Competencies of Care Providers for Enhanced service Delivery (SCOPE)_944
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Center for Integrated Health Programs	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16827



Mechanism Name: Strengthening Skills and Competencies of Care Providers for Enhanced			
Prime Partner Name: service Delivery (SCOPE)_944			
		Center for Integrated Health Programs	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	680
HRH_PRE	By Graduates: Nurses	240
HRH_PRE	By Graduates: Midwives	200
HRH_PRE	By Graduates: Other	240
HRH_PRE	Sum of Graduates disaggreagtes	680

Implementing Mechanism Details

Mechanism ID: 16828	Mechanism Name: Capacitating Laboratories for Accreditation, Strengthening and Sustainability (CLASS)_667
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: AIDS Prevention Initiative in Nigeria, LTD	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 318,775	
Total All Funding Sources and Applied Pipeline Amount: 318,775	



Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16828		
Mechanism Name:	Capacitating Laboratories for Accreditation, Strengthening and Sustainability (CLASS)_667		
Prime Partner Name:	AIDS Prevention Initiative in Nigeria, LTD		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16838	Mechanism Name: Nigerian Alliance for Health System Strengthening (NAHSS)_656
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland Baltimore	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 400,000	
---	--



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 400,000	
Funding Source	Funding Amount
GHP-State	400,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	107,120
----------------------------	---------

Budget Code Information

Mechanism ID:	16838		
Mechanism Name:	Nigerian Alliance for Health System Strengthening (NAHSS)_656		
Prime Partner Name:	University of Maryland Baltimore		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	400,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16839	Mechanism Name: Strengthening Health Human Resources in Nigeria Group (SHARING)_902
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Institute of Human Virology, Nigeria	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16839		
Mechanism Name:	Strengthening Health Human Resources in Nigeria Group		
Prime Partner Name:	(SHARING)_902		
	Institute of Human Virology, Nigeria		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	7,684
OVC_SERV_DSD	Age/Sex: 18+ Male	384
OVC_SERV_DSD	Age/Sex: 18+ Female	386
OVC_SERV_DSD	Sum of Age/Sex disaggregates	770
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	3,457



OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	3,457
--------------	-----------------------------------	-------

Implementing Mechanism Details

Mechanism ID: 16848	Mechanism Name: Sustainable HIV care and Treatment Action in Nigeria (SUSTAIN)_934
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Caritas Foundation of Nigeria (CCFN)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 6,428,971	
Applied Pipeline Amount: 4,311,422	
Total All Funding Sources and Applied Pipeline Amount: 10,740,393	
Funding Source	Funding Amount
GHP-State	6,428,971

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Commodities	142,000
Economic Strengthening	250,000
Gender: GBV	372,328
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building



Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	40,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Implementation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Water	41,394

Budget Code Information

Mechanism ID:	16848
----------------------	--------------



Mechanism Name: Sustainable HIV care and Treatment Action in Nigeria (SUSTAIN)_934			
Prime Partner Name: Catholic Caritas Foundation of Nigeria (CCFN)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,598,988	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,672,818	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	372,483	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	405,907	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,138,303	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	240,472	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	61,743
PMTCT_ART_DSD	New on ART	1,239
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	851
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	61,743
PMTCT_STAT_DSD	Number of new ANC and L&D clients	64,997
PMTCT_STAT_DSD	By: Known positives at entry	1,187
PMTCT_STAT_DSD	By: Number of new positives identified	1,012
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	2,199
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	374,233
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	17,517
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	129,354
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	19,750
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	207,612
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	37,267
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	336,966
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	374,233
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	475
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+	5,146



	Male	
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	600
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	6,757
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	663
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	193,154
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	37,265
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	350
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	37
HTC_TST_DSD	Service Delivery Point (Facility): VCT	71,552
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	877
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	61,726
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	7,947
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	662
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,834
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	3,150
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	71
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,568
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	52
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,143
GEND_GBV_DSD	Number of people receiving post-GBV care	838
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	187



GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	651
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	583
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	34,999
OVC_SERV_DSD	Age/Sex: 18+ Male	1,747
OVC_SERV_DSD	Age/Sex: 18+ Female	1,752
OVC_SERV_DSD	Sum of Age/Sex disaggregates	3,499
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	15,750
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	15,750
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	486
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	536
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	7
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	216
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	11
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	252
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB	80,268

	symptoms at the last clinical visit at a HIV facility during the reporting period.	
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	2,454
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	20,066
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	2,494
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	55,254
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	1,846
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	1,662
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	3
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1,494
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,580
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	529
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,109
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	20
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	5
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	66,354
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,585
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	16,277
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,618
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	44,874
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	5,203
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	61,151
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	66,354



TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	12,323
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	370
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	5,424
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	419
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	6,110
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	12,323
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	59,716
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	66,354
TX_PVLS_DSD	Numerator: Indication: Routine	47,775
TX_PVLS_DSD	Numerator: Indication: Targeted	11,941
TX_PVLS_DSD	Denominator: Indication: Routine	53,084
TX_PVLS_DSD	Denominator: Indication: Targeted	13,270
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	1,833
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	14,920
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	1,873
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	41,090
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	2,039
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	16,575
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	2,081
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	45,659
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	15,474
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	18,205
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of	455



	adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,930
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	463
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10,626
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	539
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,617
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	542
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12,507
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	28
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	28



LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	25
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	23
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	23
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	21
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	0
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	0
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	0
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	0
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	0
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	0
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	0
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	0
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of	0



	laboratories that achieve acceptable successful passing criteria in this PT program	
--	---	--

Implementing Mechanism Details

Mechanism ID: 16850	Mechanism Name: Comprehensive AIDS Response Enhanced for Sustainability (CARES)_924
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: AIDS Prevention Initiative in Nigeria, LTD	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 15,933,832	
Applied Pipeline Amount: 4,225,006	
Total All Funding Sources and Applied Pipeline Amount: 20,158,838	
Funding Source	Funding Amount
GHP-State	15,933,832

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	30,000
Food and Nutrition: Commodities	51,349
Economic Strengthening	239,628
Education	10,270
Gender: GBV	747,810
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation



Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	145,110
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Water	42,394

Budget Code Information

Mechanism ID:	16850		
Mechanism Name:	Comprehensive AIDS Response Enhanced for Sustainability		
Prime Partner Name:	(CARES)_924		
	AIDS Prevention Initiative in Nigeria, LTD		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	4,316,614	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	3,509,951	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	437,994	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	PDCS	684,117	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,843,378	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,801,346	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	340,432	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	192,971
PMTCT_ART_DSD	New on ART	3,922
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,448
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	192,971
PMTCT_STAT_DSD	Number of new ANC and L&D clients	203,126
PMTCT_STAT_DSD	By: Known positives at entry	3,313
PMTCT_STAT_DSD	By: Number of new positives identified	2,336
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	5,649
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,064,414
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	27,675
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	381,901
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	35,770
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	619,068
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	63,445
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	1,000,969
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	1,064,414
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	823
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	9,281
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	1,027



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	18,102
HTC_TST_DSD	Service Delivery Point (Community): Index testing	28,644
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	9,547
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	133,670
HTC_TST_DSD	Service Delivery Point (Community): Other	19,096
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	1,504
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	436,232
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	58,879
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	780
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	82
HTC_TST_DSD	Service Delivery Point (Facility): VCT	163,554
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	192,971
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	17,951
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	1,504
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	5,042
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	5,599
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	147
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,209
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	93
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,101



GEND_GBV_DSD	Number of people receiving post-GBV care	1,237
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	393
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	844
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	844
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	77,976
OVC_SERV_DSD	Age/Sex: 18+ Male	3,900
OVC_SERV_DSD	Age/Sex: 18+ Female	4,079
OVC_SERV_DSD	Sum of Age/Sex disaggregates	7,979
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	34,907
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	35,090
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	917
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,019
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	20
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	415
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	23
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with	459

	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	109,836
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	1,914
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	34,410
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	1,418
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	72,094
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	2,364
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	2,124
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1,918
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,370
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	2,000
PMTCT_EID_DSD	Sum of Infant Age disaggregates	5,370
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	55
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	36
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	86,033
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,577
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	23,292
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,738
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	57,426



TX_CURR_DSD	Sum of Aggregated Age/Sex <15	5,315
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	80,718
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	86,033
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	27,691
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	945
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	12,063
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,074
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	13,609
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	27,691
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	77,430
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	86,034
TX_PVLS_DSD	Numerator: Indication: Routine	61,941
TX_PVLS_DSD	Numerator: Indication: Targeted	15,489
TX_PVLS_DSD	Denominator: Indication: Routine	68,826
TX_PVLS_DSD	Denominator: Indication: Targeted	17,208
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	1,661
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	20,606
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	1,523
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	53,640
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	1,846
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	22,897
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	1,690
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	59,601
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	33,956
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting	39,947



	period, including those who have died, those who have stopped ART, and those lost to follow-up	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	762
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9,039
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	685
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	23,470
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	853
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10,753
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	813
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	27,528
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories	31



	that perform this testing	
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	31
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	28
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	23
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	23
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	21
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	3
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	3
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	3
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	3
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	3
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	3

Implementing Mechanism Details

Mechanism ID: 16852	Mechanism Name: Development of a Laboratory Network and Society to Implement a Quality Systems_710
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Society for Laboratory Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



G2G: No	Managing Agency:
Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16852		
Mechanism Name:	Development of a Laboratory Network and Society to Implement a Quality Systems_710		
Prime Partner Name:	African Society for Laboratory Medicine		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16853	Mechanism Name: Partnership for Medical Education and Training (PMET)_916
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Center for Clinical Care and Clinical Research Ltd	

Approved



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 700,000	
Applied Pipeline Amount: 690,000	
Total All Funding Sources and Applied Pipeline Amount: 1,390,000	
Funding Source	Funding Amount
GHP-State	700,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	90,261
----------------------------	--------

Budget Code Information

Mechanism ID:	16853		
Mechanism Name:	Partnership for Medical Education and Training (PMET)_916		
Prime Partner Name:	Center for Clinical Care and Clinical Research Ltd		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	700,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 16854	Mechanism Name: Service Expansion and Early Detection for Sustainable HIV Care (SEEDS)_ 868
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Center for Clinical Care and Clinical Research Ltd	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 4,906,228	
Applied Pipeline Amount: 561,166	
Total All Funding Sources and Applied Pipeline Amount: 5,467,394	
Funding Source	Funding Amount
GHP-State	4,906,228

Cross-Cutting Budget Attribution(s)

Human Resources for Health	581,808
Economic Strengthening	50,145
Food and Nutrition: Commodities	60,201
Gender: GBV	201,610
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	45,000



Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID:	16854		
Mechanism Name:	Service Expansion and Early Detection for Sustainable HIV Care		
Prime Partner Name:	(SEEDS)_868 Center for Clinical Care and Clinical Research Ltd		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	691,090	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HKID	988,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	309,466	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	207,204	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	720,501	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,935,741	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	54,226	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	116,489
PMTCT_ART_DSD	New on ART	1,334
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	852
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	116,489
PMTCT_STAT_DSD	Number of new ANC and L&D clients	122,786
PMTCT_STAT_DSD	By: Known positives at entry	911
PMTCT_STAT_DSD	By: Number of new positives identified	1,384
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	2,295
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	264,219
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	15,139
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	54,220
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	17,073
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	177,787
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	32,212
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	232,007
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	264,219
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	164
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+	1,786



	Male	
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	227
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	2,089
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	615
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	81,424
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	31,751
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	146
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	11
HTC_TST_DSD	Service Delivery Point (Facility): VCT	30,350
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	116,647
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	3,005
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	270
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,364
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,515
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	33
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	722
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	29
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	580
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	25,045



OVC_SERV_DSD	Age/Sex: 18+ Male	1,251
OVC_SERV_DSD	Age/Sex: 18+ Female	11,270
OVC_SERV_DSD	Sum of Age/Sex disaggregates	12,521
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	1,253
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	11,271
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	235
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	262
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	119
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	114
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	36,663
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	970
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	9,758
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	410
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	25,525



TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	842
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	758
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	684
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,619
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	568
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,187
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	43
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	17
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	35,607
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	925
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	10,428
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	756
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	23,498
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,681
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	33,926
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	35,607
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,473
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	104
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,976
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	120
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,273



TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	4,473
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	32,048
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	35,606
TX_PVLS_DSD	Numerator: Indication: Routine	25,638
TX_PVLS_DSD	Numerator: Indication: Targeted	6,410
TX_PVLS_DSD	Denominator: Indication: Routine	28,485
TX_PVLS_DSD	Denominator: Indication: Targeted	7,121
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	910
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	9,192
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	836
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	21,110
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	1,013
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	10,211
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	930
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	23,452
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,477
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	5,267
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	110
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,314
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on	102



	treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,951
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	138
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,536
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	116
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,477
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	28
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	28
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	25
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	28
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	28
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable	25



	successful passing criteria in this PT program	
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1

Implementing Mechanism Details

Mechanism ID: 16855	Mechanism Name: Bridges Plus_928
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Center for Integrated Health Programs	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 21,567,887	
Applied Pipeline Amount: 2,112,586	
Total All Funding Sources and Applied Pipeline Amount: 23,680,473	
Funding Source	Funding Amount
GHP-State	21,567,887

Cross-Cutting Budget Attribution(s)

Human Resources for Health	431,100
Food and Nutrition: Commodities	59,743



Economic Strengthening	128,406
Education	62,453
Water	97,650
Renovation	272,365
Gender: GBV	760,432
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Motor Vehicles: Purchased	79,578

Budget Code Information

Mechanism ID:	16855		
Mechanism Name:	Bridges Plus_928		
Prime Partner Name:	Center for Integrated Health Programs		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	7,619,358	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	3,548,763	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	647,948	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	732,209	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	3,946	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,330,904	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	7,029,776	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	624,983	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	163,154
PMTCT_ART_DSD	New on ART	2,402
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,853
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	163,154
PMTCT_STAT_DSD	Number of new ANC and L&D clients	171,740
PMTCT_STAT_DSD	By: Known positives at entry	2,345
PMTCT_STAT_DSD	By: Number of new positives identified	2,135
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	4,480
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	826,643
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	29,239
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	282,642
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	32,583
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	482,179
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	61,822
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	764,821
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	826,643
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	969



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	10,505
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	1,207
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	13,857
HTC_TST_DSD	Service Delivery Point (Community): Index testing	4,194
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	23,905
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	7,968
HTC_TST_DSD	Service Delivery Point (Community): Other	5,890
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	1,321
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	393,849
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	61,496
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	842
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	60
HTC_TST_DSD	Service Delivery Point (Facility): VCT	146,540
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	163,140
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	16,098
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	1,340
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	6,170
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	6,851
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	127
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,263
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with	110



	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,736
GEND_GBV_DSD	Number of people receiving post-GBV care	1,427
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	325
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,102
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	993
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	83,820
OVC_SERV_DSD	Age/Sex: 18+ Male	4,186
OVC_SERV_DSD	Age/Sex: 18+ Female	37,718
OVC_SERV_DSD	Sum of Age/Sex disaggregates	41,904
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	4,193
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	37,723
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,066
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,185
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	24
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	509
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with	24

	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	509
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	209,029
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	5,858
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	54,740
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	5,607
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	142,824
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	4,789
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	4,319
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	3,873
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,186
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,069
PMTCT_EID_DSD	Sum of Infant Age disaggregates	4,255
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	45
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	14
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	130,400
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	4,859



TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	32,827
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	4,564
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	88,150
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	9,423
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	120,977
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	130,400
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	24,011
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	686
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	10,592
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	777
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	11,956
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	24,011
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	117,681
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	130,754
TX_PVLS_DSD	Numerator: Indication: Routine	94,151
TX_PVLS_DSD	Numerator: Indication: Targeted	23,530
TX_PVLS_DSD	Denominator: Indication: Routine	104,192
TX_PVLS_DSD	Denominator: Indication: Targeted	26,562
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	3,400
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	30,111
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	3,273
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	80,897
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	3,775
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	33,438
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	3,657
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	89,884
TX_RET_DSD	Number of adults and children who are still alive and on	24,565



	treatment at 12 months after initiating ART	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	28,884
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	715
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,080
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	699
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17,071
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	851
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,167
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	808
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	20,058



	including those who have died, those who have stopped ART, and those lost to follow-up)	
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	78
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	78
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	70
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	67
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	67
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	60
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1

Implementing Mechanism Details

Mechanism ID: 16871	Mechanism Name: Action Plus-Up_925
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Institute of Human Virology, Nigeria	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 20,099,773	
Applied Pipeline Amount: 13,626,019	
Total All Funding Sources and Applied Pipeline Amount: 33,725,792	
Funding Source	Funding Amount
GHP-State	20,099,773

Cross-Cutting Budget Attribution(s)

Economic Strengthening	297,187
Food and Nutrition: Commodities	100,000
Human Resources for Health	345,077
Education	100,000
Motor Vehicles: Purchased	250,000
Key Populations: MSM and TG	50,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	79,698
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on



	sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	956,061
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research



Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Renovation	860,000
Water	42,394

Budget Code Information

Mechanism ID:	16871
----------------------	--------------



Mechanism Name: Action Plus-Up_925			
Prime Partner Name: Institute of Human Virology, Nigeria			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	8,006,586	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	4,457,856	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,545,588	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	1,340,829	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,882,336	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	866,578	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	259,744
PMTCT_ART_DSD	New on ART	5,155
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	3,525
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	259,744
PMTCT_STAT_DSD	Number of new ANC and L&D clients	273,005
PMTCT_STAT_DSD	By: Known positives at entry	3,764
PMTCT_STAT_DSD	By: Number of new positives identified	5,221
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	8,985
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,171,138
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	63,454
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	365,447
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION	71,573



	ONLY: <15 Female	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	670,664
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	135,027
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	1,036,111
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	1,171,138
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Negative <15 Male	3
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Negative 15+ Male	104
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Negative <15 Female	4
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Negative 15+ Female	919
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	1,677
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	14,450
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	1,965
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	19,103
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	210,454
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	1,375
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	397,099
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	134,781
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	704
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	48
HTC_TST_DSD	Service Delivery Point (Facility): VCT	148,984
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	27
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	259,931
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	16,363
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	1,372



TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	9,496
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	10,593
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	241
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5,057
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	182
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,016
GEND_GBVDSD	Number of people receiving post-GBV care	18,256
GEND_GBVDSD	Age/Sex: <10 Male	33
GEND_GBVDSD	Age/Sex: 10-14 Male	554
GEND_GBVDSD	Age/Sex: 20-24 Male	22
GEND_GBVDSD	Age/Sex: 25-49 Male	5,117
GEND_GBVDSD	Age/Sex: <10 Female	31
GEND_GBVDSD	Age/Sex: 10-14 Female	493
GEND_GBVDSD	Age/Sex: 20-24 Female	135
GEND_GBVDSD	Age/Sex: 25-49 Female	11,496
GEND_GBVDSD	Sum of Age/Sex Disaggregates	1,111
GEND_GBVDSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	4,091
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	14,165
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	12,751
GEND_GBVDSD	Age/Sex: 15-19 Female	31
GEND_GBVDSD	Age/Sex: 15-19 male	27



OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	99,190
OVC_SERV_DSD	Age/Sex: 18+ Male	4,954
OVC_SERV_DSD	Age/Sex: 18+ Female	4,960
OVC_SERV_DSD	Sum of Age/Sex disaggregates	9,914
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	44,632
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	44,644
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,603
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,792
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	26
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	719
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	29
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	829
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	208,969
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	7,154



TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	55,663
TB_SCREENDX_DSD	Screened for TB by Age/Sex: <15 Female	4,577
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	141,575
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	4,818
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	4,338
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	3,901
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	5,184
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	3,487
PMTCT_EID_DSD	Sum of Infant Age disaggregates	8,671
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	109
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	87
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	169,335
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	6,075
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	46,036
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	6,771
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	110,453
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	12,846
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	156,489
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	169,335
TX_CURR_DSD	Age/Sex: <1	0
TX_CURR_DSD	Age/Sex: <1-9	0
TX_NEW_DSD	Number of adults and children newly enrolled on	36,086



	antiretroviral therapy (ART)	
TX_NEW_DSD	By Age/Sex: <1	0
TX_NEW_DSD	By Age/Sex: 1-9	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1,510
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	15,391
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,729
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	17,456
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	36,086
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	152,662
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	175,523
TX_PVLS_DSD	Numerator: Indication: Routine	122,113
TX_PVLS_DSD	Numerator: Indication: Targeted	30,549
TX_PVLS_DSD	Denominator: Indication: Routine	140,382
TX_PVLS_DSD	Denominator: Indication: Targeted	35,141
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	2,696
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	43,194
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	2,655
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	104,117
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	2,956
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	49,694
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	2,952
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	119,921
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	79,619
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	93,670



TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,587
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22,072
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,421
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	54,539
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,866
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	25,973
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,674
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	64,157
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	63
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories	63



	that participate in this PT program	
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	63
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	43
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	43
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	43
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	6
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	6
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	6
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	6
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	6
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	6

Implementing Mechanism Details

Mechanism ID: 17195	Mechanism Name: HIFASS
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: Health Initiatives for Safety and Stability in Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 822,000	



Total All Funding Sources and Applied Pipeline Amount: 822,000	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17195			
Mechanism Name: HIFASS			
Prime Partner Name: Health Initiatives for Safety and Stability in Africa			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Approved



Treatment	HTXS	0	0
-----------	------	---	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17727	Mechanism Name: MSH - Prevention Organisation Systems AIDS Care and Treatment(MSH -ProACT)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 3,836,579	
Total All Funding Sources and Applied Pipeline Amount: 3,836,579	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17727
Mechanism Name:	MSH - Prevention Organisation Systems AIDS Care and Treatment(MSH -ProACT)
Prime Partner Name:	Management Sciences for Health



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2017
PMTCT_ART_DSD	New on ART	0
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	0
PMTCT_STAT_DSD	By: Known positives at entry	0
PMTCT_STAT_DSD	By: Number of new positives identified	0
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	0
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	0
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	0
PMTCT_EID_DSD	Sum of Infant Age disaggregates	0
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	0

Implementing Mechanism Details

Mechanism ID: 17728	Mechanism Name: Sustainable Mechanism for Improving Livelihood & Household Empowerment (SMILE)
---------------------	---



Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 4,989,384	
Applied Pipeline Amount: 7,346,395	
Total All Funding Sources and Applied Pipeline Amount: 12,335,779	
Funding Source	Funding Amount
GHP-State	4,989,384

Cross-Cutting Budget Attribution(s)

Human Resources for Health	572,937
Economic Strengthening	2,334,096
Education	578,417
Water	212,707
Gender: GBV	170,684
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: Gender Equality	85,342
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building



Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Food and Nutrition: Commodities	1,035,201

Budget Code Information

Mechanism ID:	17728
---------------	-------



Mechanism Name:	Sustainable Mechanism for Improving Livelihood & Household		
Prime Partner Name:	Empowerment (SMILE) Catholic Relief Services		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	4,989,384	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	288,131
OVC_SERV_DSD	Age/Sex: 18+ Male	49,443
OVC_SERV_DSD	Age/Sex: 18+ Female	45,641
OVC_SERV_DSD	Sum of Age/Sex disaggregates	95,084
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	100,381
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	92,666

Implementing Mechanism Details

Mechanism ID: 17729	Mechanism Name: Systems Transformed for Empowered Action and Enabling Responses for Vulnerable Children and Families (STEER)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Save the Children US	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,529,518	
Applied Pipeline Amount: 5,171,506	
Total All Funding Sources and Applied Pipeline Amount: 7,701,024	
Funding Source	Funding Amount



GHP-State	2,529,518
-----------	-----------

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	1,633,157
Economic Strengthening	400
Education	408,200
Motor Vehicles: Purchased	91,653
Gender: GBV	290,407
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	273,801
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID:	17729		
Mechanism Name:	Systems Transformed for Empowered Action and Enabling Responses for Vulnerable Children and Families (STEER)		
Prime Partner Name:	Save the Children US		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	2,529,518	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	197,351
OVC_SERV_DSD	Age/Sex: 18+ Male	14,852
OVC_SERV_DSD	Age/Sex: 18+ Female	16,735



OVC_SERV_DSD	Sum of Age/Sex disaggregates	31,587
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	77,906
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	87,858

Implementing Mechanism Details

Mechanism ID: 17733	Mechanism Name: Strengthening Partnerships, Results and Innovations in Nutrition Globally (SPRING)		
Funding Agency: USAID	Procurement Type: Cooperative Agreement		
Prime Partner Name: John Snow Inc (JSI)			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
G2G: No		Managing Agency:	

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17733		
Mechanism Name:	Strengthening Partnerships, Results and Innovations in Nutrition Globally (SPRING)		
Prime Partner Name:	John Snow Inc (JSI)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HKID	0	0
------	------	---	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17734	Mechanism Name: Challenge TB
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: KNCV Tuberculosis Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,816	
Applied Pipeline Amount: 550,270	
Total All Funding Sources and Applied Pipeline Amount: 552,086	
Funding Source	Funding Amount
GHP-State	1,816

Cross-Cutting Budget Attribution(s)

Gender: GBV	1,816
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building

Budget Code Information

Mechanism ID:	17734
----------------------	--------------



Mechanism Name:	Challenge TB		
Prime Partner Name:	KNCV Tuberculosis Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,816	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	578
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	14
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	311
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	13
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	240
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	27
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	551
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	578
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	578
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	578
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	642
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with	14



	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	311
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	13
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	240

Implementing Mechanism Details

Mechanism ID: 17735	Mechanism Name: SHiPS for MARPs
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Society for Family Health-Nigeria	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 954,963	
Applied Pipeline Amount: 6,461,996	
Total All Funding Sources and Applied Pipeline Amount: 7,416,959	
Funding Source	Funding Amount
GHP-State	954,963

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	40,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building



Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: GBV	665,906
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation



Key Populations: MSM and TG	67,684
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	23,051
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs

Budget Code Information

Mechanism ID:	17735
----------------------	-------



Mechanism Name:	SHiPS for MARPs		
Prime Partner Name:	Society for Family Health-Nigeria		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	954,963	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	83,158
KP_PREV_DSD	Total estimated number of key population in the catchment area	104,153
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	19,461
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	61,917

KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,422
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	358
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	4,996
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	96,953
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	1,486
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	718
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	93,089
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	70,278
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	17,571
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	87,849



HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	87,849
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,634
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,576
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	93,300
GEND_GBV_DSD	Number of people receiving post-GBV care	3,371
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,655
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,657
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	192
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	74
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	118
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	192
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	192
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	226
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	91
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	135
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	226

Implementing Mechanism Details

Mechanism ID: 17737	Mechanism Name: Local Partner for Orphans and Vulnerable Children 3
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Health Initiatives for Safety and Stability in Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,882,163	
Applied Pipeline Amount: 1,410,771	



Total All Funding Sources and Applied Pipeline Amount: 3,292,934	
Funding Source	Funding Amount
GHP-State	1,882,163

Cross-Cutting Budget Attribution(s)

Economic Strengthening	164,574
Gender: GBV	46,291
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Gender: Gender Equality	130,946
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Food and Nutrition: Commodities	15,762
Motor Vehicles: Purchased	103,015

Budget Code Information

Mechanism ID: 17737			
Mechanism Name: Local Partner for Orphans and Vulnerable Children 3			
Prime Partner Name: Health Initiatives for Safety and Stability in Africa			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,882,163	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,750
HTC_TST_DSD	Age/sex: 10-14 Male	281
HTC_TST_DSD	Age/sex: 15-19 Male	116
HTC_TST_DSD	Age/sex: 20-24 Male	0
HTC_TST_DSD	Age/sex: 25-49 Male	0
HTC_TST_DSD	Age/sex: 50+ Male	0
HTC_TST_DSD	Age/sex: 10-14 Female	281
HTC_TST_DSD	Age/sex: 15-19 Female	116
HTC_TST_DSD	Age/sex: 20-24 Female	0
HTC_TST_DSD	Age/sex: 25-49 Female	0



HTC_TST_DSD	Age/sex: 50+ Female	0
HTC_TST_DSD	Sum of Age/Sex disaggregates	794
HTC_TST_DSD	Age/sex: <1	74
HTC_TST_DSD	Age/sex: 1-9	882
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	79,860
OVC_SERV_DSD	Age/Sex: 18+ Male	0
OVC_SERV_DSD	Age/Sex: 18+ Female	0
OVC_SERV_DSD	Sum of Age/Sex disaggregates	0
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	39,929
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	39,932

Implementing Mechanism Details

Mechanism ID: 17739	Mechanism Name: UNICEF
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: United Nations Children's Fund	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 999,426	
Total All Funding Sources and Applied Pipeline Amount: 999,426	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	17739		
Mechanism Name:	UNICEF		
Prime Partner Name:	United Nations Children's Fund		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17742	Mechanism Name: Supporting Universal Comprehensive and Sustainable HIV/AIDS Services (SUCCESS)_922
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Friends for Global Health Initiative in Nigeria	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,523,622	
Applied Pipeline Amount: 1,028,019	
Total All Funding Sources and Applied Pipeline Amount: 2,551,641	
Funding Source	Funding Amount
GHP-State	1,523,622

Cross-Cutting Budget Attribution(s)

Human Resources for Health	17,725
Gender: Gender Equality	6,375
Focus Area:	Changing harmful gender norms and promoting positive gender norms



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: GBV	58,991
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation



Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID:	17742		
Mechanism Name:	Supporting Universal Comprehensive and Sustainable HIV/AIDS Services (SUCCESS)_922		
Prime Partner Name:	Friends for Global Health Initiative in Nigeria		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	461,508	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	289,090	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	107,669	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	268	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	140,447	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	492,084	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	32,556	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	48,143
PMTCT_ART_DSD	New on ART	197
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	222
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	48,143
PMTCT_STAT_DSD	Number of new ANC and L&D clients	50,680
PMTCT_STAT_DSD	By: Known positives at entry	246
PMTCT_STAT_DSD	By: Number of new positives identified	196
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	442
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	141,692
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,158
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	40,807
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION	3,567



	ONLY: <15 Female	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	94,160
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	6,725
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	134,967
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	141,692
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	100
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,124
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	130
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,288
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	206
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	61,050
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	6,681
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	104
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	6
HTC_TST_DSD	Service Delivery Point (Facility): VCT	22,794
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	48,153
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	2,501
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	197
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	856
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	951
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	16
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with	376



	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	19
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	445
GEND_GBV_DSD	Number of people receiving post-GBV care	200
GEND_GBV_DSD	Age/Sex: <10 Male	0
GEND_GBV_DSD	Age/Sex: 10-14 Male	6
GEND_GBV_DSD	Age/Sex: 20-24 Male	0
GEND_GBV_DSD	Age/Sex: 25-49 Male	55
GEND_GBV_DSD	Age/Sex: 50+ Male	0
GEND_GBV_DSD	Age/Sex: <10 Female	0
GEND_GBV_DSD	Age/Sex: 10-14 Female	5
GEND_GBV_DSD	Age/Sex: 20-24 Female	1
GEND_GBV_DSD	Age/Sex: 25-49 Female	133
GEND_GBV_DSD	Age/Sex: 50+ Female	0
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	11
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	45
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	155
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	229
GEND_GBV_DSD	Age/Sex: 15-19 Female	0
GEND_GBV_DSD	Age/Sex: 15-19 male	0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	7,329
OVC_SERV_DSD	Age/Sex: 18+ Male	366
OVC_SERV_DSD	Age/Sex: 18+ Female	366
OVC_SERV_DSD	Sum of Age/Sex disaggregates	732
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	3,298



OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	3,299
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	150
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	163
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	71
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	74
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	22,644
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	586
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	6,009
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	285
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	15,764
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	522
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	467
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear	0



	only	
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	421
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	204
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	215
PMTCT_EID_DSD	Sum of Infant Age disaggregates	419
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	3
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	2
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	17,502
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	432
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	5,398
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	451
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	11,221
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	883
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	16,619
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	17,502
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,524
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	41
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,145
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	51
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,287
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,524
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting	15,752



	laboratory results within the past 12 months.	
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	17,502
TX_PVLS_DSD	Numerator: Indication: Routine	12,600
TX_PVLS_DSD	Numerator: Indication: Targeted	3,152
TX_PVLS_DSD	Denominator: Indication: Routine	14,002
TX_PVLS_DSD	Denominator: Indication: Targeted	3,500
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	442
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	4,801
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	518
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	9,991
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	494
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	5,335
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	575
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	11,098
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,341
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,753
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	65
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	730
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	70
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,476



TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	78
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	856
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	84
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,735
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	13
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	13
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	12
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	13
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	13
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	12
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that	1



	participate in this PT program	
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1

Implementing Mechanism Details

Mechanism ID: 17743	Mechanism Name: Integrated Programs for Sustainable Action Against HIV/AIDS in Nigeria (IPSAN)_929
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Pro-Health International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 869,142	
Applied Pipeline Amount: 191,943	
Total All Funding Sources and Applied Pipeline Amount: 1,061,085	
Funding Source	Funding Amount
GHP-State	869,142

Cross-Cutting Budget Attribution(s)

Gender: GBV	43,341
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building



Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	10,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Human Resources for Health	40,000
Food and Nutrition: Commodities	20,000

Budget Code Information

Mechanism ID:	17743
----------------------	--------------



Mechanism Name: Integrated Programs for Sustainable Action Against HIV/AIDS in Nigeria			
Prime Partner Name: (IPSAN)_929 Pro-Health International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	192,570	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	214,229	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	72,164	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	38,626	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	334,053	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	17,500	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	12,216
PMTCT_ART_DSD	New on ART	79
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	78
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	12,216
PMTCT_STAT_DSD	Number of new ANC and L&D clients	12,858
PMTCT_STAT_DSD	By: Known positives at entry	91
PMTCT_STAT_DSD	By: Number of new positives identified	87
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	178
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	62,143
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,389
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	20,077
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,822
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	34,855
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	7,211
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	54,932
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	62,143
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	33
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	381
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	45
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+	524



	Female	
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	104
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	29,984
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	7,211
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	51
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	3
HTC_TST_DSD	Service Delivery Point (Facility): VCT	11,238
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	12,216
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	1,232
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	104
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,521
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,691
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	28
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	593
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	40
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	860
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	5,430
OVC_SERV_DSD	Age/Sex: 18+ Male	268
OVC_SERV_DSD	Age/Sex: 18+ Female	270
OVC_SERV_DSD	Sum of Age/Sex disaggregates	538

OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	2,446
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	2,446
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	261
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	289
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	119
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	7
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	129
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	7,999
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	215
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	2,161
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	181
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	5,442
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	185
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	165



TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	149
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	109
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	49
PMTCT_EID_DSD	Sum of Infant Age disaggregates	158
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	6
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	2
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	6,133
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	135
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,663
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	112
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	4,223
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	247
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	5,886
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	6,133
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	885
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	13
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	401
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	17
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	454
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	885
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml)	5,519



	documented in the medical records and /or supporting laboratory results within the past 12 months.	
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	6,133
TX_PVLS_DSD	Numerator: Indication: Routine	4,416
TX_PVLS_DSD	Numerator: Indication: Targeted	1,103
TX_PVLS_DSD	Denominator: Indication: Routine	4,906
TX_PVLS_DSD	Denominator: Indication: Targeted	1,227
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	149
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	1,481
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	131
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	3,758
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	164
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	1,646
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	146
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	4,177
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	928
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,093
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	26
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	251
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	21
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on	630



	treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	29
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	294
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	26
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	744
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	6
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	6
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	5
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	6
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	6
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	5
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	0



LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	0
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	0
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	0
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	0
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	0
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	0
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	0
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0

Implementing Mechanism Details



Mechanism ID: 17744	Mechanism Name: Local Capacity Enhancement (LOCATE)_867
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Excellence Community Education Welfare Scheme (ECEWS)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 950,622	
Applied Pipeline Amount: 130,721	
Total All Funding Sources and Applied Pipeline Amount: 1,081,343	
Funding Source	Funding Amount
GHP-State	950,622

Cross-Cutting Budget Attribution(s)

Human Resources for Health	104,824
Economic Strengthening	10,000
Gender: GBV	5,358
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	24,389
Focus Area:	Changing harmful gender norms and promoting



	positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Food and Nutrition: Commodities	3,188

Budget Code Information



Mechanism ID: 17744			
Mechanism Name: Local Capacity Enhancement (LOCATE)_867			
Prime Partner Name: Excellence Community Education Welfare Scheme (ECEWS)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	82,865	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	26,138	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	81,423	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	93,840	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	148	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	426,078	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	226,204	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	13,926	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	83,809
PMTCT_ART_DSD	New on ART	606
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	394
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	83,809
PMTCT_STAT_DSD	Number of new ANC and L&D clients	88,605
PMTCT_STAT_DSD	By: Known positives at entry	436
PMTCT_STAT_DSD	By: Number of new positives identified	654
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,090
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	109,938
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,343
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	10,751
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,514
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	96,330
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	2,857
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	107,081
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	109,938
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	8
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	91
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	11
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+	787



	Female	
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	55
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	16,052
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	2,857
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	29
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	2
HTC_TST_DSD	Service Delivery Point (Facility): VCT	6,020
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	84,206
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	662
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	55
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	499
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	554
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	157
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	15
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	320
GEND_GBV_DSD	Number of people receiving post-GBV care	38
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	6
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	32
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	28



OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	663
OVC_SERV_DSD	Age/Sex: 18+ Male	0
OVC_SERV_DSD	Age/Sex: 18+ Female	0
OVC_SERV_DSD	Sum of Age/Sex disaggregates	0
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	319
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	344
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	84
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	755
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	37
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	44
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	3,525
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	20



TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	688
TB_SCREENDX_DSD	Screened for TB by Age/Sex: <15 Female	53
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	2,764
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	82
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	73
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	66
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	587
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	413
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,000
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	3
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	11
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,359
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	74
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	925
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	68
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,292
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	142
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	3,217
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	3,359
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,212
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	9



TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	559
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	12
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	632
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,212
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	3,565
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	3,235
TX_PVLS_DSD	Numerator: Indication: Routine	2,852
TX_PVLS_DSD	Numerator: Indication: Targeted	713
TX_PVLS_DSD	Denominator: Indication: Routine	2,588
TX_PVLS_DSD	Denominator: Indication: Targeted	647
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	117
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	954
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	108
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	2,386
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	98
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	871
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	93
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	2,173
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	884
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,040
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	36
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of	218



	adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	31
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	599
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	42
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	259
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	37
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	702
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	9
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	9
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	8



LAB_PT_DSD	CD4: Number of laboratories that perform this testing	9
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	9
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	8
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	0
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	0
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	0
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	0
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0

Implementing Mechanism Details

Mechanism ID: 17745	Mechanism Name: Sustaining Comprehensive HIV/AIDS Response through Partnerships (SCHARP+) _937
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Achieving Health Nigeria Initiative	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 358,767	
Applied Pipeline Amount: 317,673	
Total All Funding Sources and Applied Pipeline Amount: 676,440	
Funding Source	Funding Amount



GHP-State	358,767
-----------	---------

Cross-Cutting Budget Attribution(s)

Human Resources for Health	50,450
Gender: GBV	9,411
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	145,110
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation



Motor Vehicles: Leased	15,000
------------------------	--------

Budget Code Information

Mechanism ID:	17745		
Mechanism Name:	Sustaining Comprehensive HIV/AIDS Response through Partnerships (SCHARP+) _937		
Prime Partner Name:	Achieving Health Nigeria Initiative		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	65,166	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	55,918	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	71,733	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	55,721	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	108,760	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	1,469	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	37,525
PMTCT_ART_DSD	New on ART	587
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	159
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	37,525
PMTCT_STAT_DSD	Number of new ANC and L&D clients	39,504
PMTCT_STAT_DSD	By: Known positives at entry	314
PMTCT_STAT_DSD	By: Number of new positives identified	440
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	754
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	38,169
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	17
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	283
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	20
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	37,849
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	37
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	38,132
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	38,169



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	441
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	426
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	37
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	0
HTC_TST_DSD	Service Delivery Point (Facility): VCT	158
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	37,530
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	18
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	87
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	97
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	54
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	30



OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,417
OVC_SERV_DSD	Age/Sex: 18+ Male	71
OVC_SERV_DSD	Age/Sex: 18+ Female	70
OVC_SERV_DSD	Sum of Age/Sex disaggregates	141
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	638
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	638
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	15
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	17
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	7
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	2,359
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	50

TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	592
TB_SCREENDX_DSD	Screened for TB by Age/Sex: <15 Female	49
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	1,668
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	53
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	49
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	45
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	563
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	189
PMTCT_EID_DSD	Sum of Infant Age disaggregates	752
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	19
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	6
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,505
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	8
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	401
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,094
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	10
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,495
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,505
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	218
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	11



TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	91
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	14
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	102
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	218
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,358
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,604
TX_PVLS_DSD	Numerator: Indication: Routine	1,085
TX_PVLS_DSD	Numerator: Indication: Targeted	272
TX_PVLS_DSD	Denominator: Indication: Routine	1,283
TX_PVLS_DSD	Denominator: Indication: Targeted	321
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	35
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	348
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	34
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	941
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	38
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	411
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	35
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	1,120
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	57
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	67
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of	13



	adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	43
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	16
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	50
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	7
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	7
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	6



LAB_PT_DSD	CD4: Number of laboratories that perform this testing	7
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	7
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	6
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	0
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	0
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	0
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	0
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	0
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	0
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0

Implementing Mechanism Details



Mechanism ID: 17747	Mechanism Name: Henry Jackson Foundation
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: Henry Jackson Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 4,692,362	
Applied Pipeline Amount: 3,120,890	
Total All Funding Sources and Applied Pipeline Amount: 7,813,252	
Funding Source	Funding Amount
GHP-State	4,692,362

Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,000,000
Key Populations: MSM and TG	100,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	150,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers



Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation



Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Condom procurement	180,000
Condom programming	100,000

Budget Code Information

Mechanism ID: 17747			
Mechanism Name: Henry Jackson Foundation			
Prime Partner Name: Henry Jackson Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,239,525	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	195,919	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	325,743	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	650,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	636,711	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,252,242	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	392,222	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	49,214
PMTCT_ART_DSD	New on ART	865
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	3,179
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	49,214
PMTCT_STAT_DSD	Number of new ANC and L&D clients	51,804
PMTCT_STAT_DSD	By: Known positives at entry	2,481
PMTCT_STAT_DSD	By: Number of new positives identified	1,776
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	4,257
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	8,063
KP_PREV_DSD	Total estimated number of key population in the catchment area	9,486
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,070
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,821
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	161



KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	11
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	3,612
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	5,672
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	189
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	13
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	118,235
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	633
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	31,807
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	714
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	85,081
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,347
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	116,888
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	118,235
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	112



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,206
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	140
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	3,122
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	29,559
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	184
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	26,750
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	1,347
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	10,080
HTC_TST_DSD	Service Delivery Point (Facility): VCT	29,559
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	49,214
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	1,101
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	149
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	165
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	85
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	57
GEND_GBV_DSD	Number of people receiving post-GBV care	413
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	93
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	320

GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	288
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	25
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	28
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	11
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	12
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	27,511
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	560
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	8,923
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	511
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	17,517
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	633
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	569

TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	513
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,033
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,011
PMTCT_EID_DSD	Sum of Infant Age disaggregates	4,044
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	23
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	8
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	27,511
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	288
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	9,099
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	262
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	17,862
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	550
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	26,961
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	27,511
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,126
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	39
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,900
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	44
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,143
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	4,126
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	24,760
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record	27,511



	and /or laboratory records in the past 12 months.	
TX_PVLS_DSD	Numerator: Indication: Routine	19,808
TX_PVLS_DSD	Numerator: Indication: Targeted	4,952
TX_PVLS_DSD	Denominator: Indication: Routine	22,009
TX_PVLS_DSD	Denominator: Indication: Targeted	5,502
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	504
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	8,031
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	460
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	15,765
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	560
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	8,923
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	511
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	17,517
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	7,101
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	8,876
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	145
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,303
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	132
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,521
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	181



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,878
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	165
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,652
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	25
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	23
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	23
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	18
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	18
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	15
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	2
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	2
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this	2



	PT program	
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	2
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	2
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	22
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	22
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	19
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	11
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	11
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	9

Implementing Mechanism Details

Mechanism ID: 17749	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18010	Mechanism Name: Local Partners for Orphans & Vulnerable Children 1
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Association for Reproductive and Family Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 3,107,796	
Applied Pipeline Amount: 586,558	
Total All Funding Sources and Applied Pipeline Amount: 3,694,354	
Funding Source	Funding Amount
GHP-State	3,107,796

Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,255,931
Economic Strengthening	507,005
Education	80,487
Gender: GBV	53,980
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Gender: Gender Equality	68,005
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation



Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research

Budget Code Information

Mechanism ID: 18010			
Mechanism Name: Local Partners for Orphans & Vulnerable Children 1			
Prime Partner Name: Association for Reproductive and Family Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	3,107,796	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	70,010
OVC_SERV_DSD	Age/Sex: 18+ Male	5,895
OVC_SERV_DSD	Age/Sex: 18+ Female	6,645
OVC_SERV_DSD	Sum of Age/Sex disaggregates	12,540



OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	26,859
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	30,611

Implementing Mechanism Details

Mechanism ID: 18070	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18075	Mechanism Name: Local Partners for Orphans & Vulnerable Children 2
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Widows and Orphans Empowerment Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,970,862	
Applied Pipeline Amount: 252,869	
Total All Funding Sources and Applied Pipeline Amount: 2,223,731	
Funding Source	Funding Amount
GHP-State	1,970,862

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Commodities	42,201
Economic Strengthening	50,251
Education	13,317
Gender: Gender Equality	169,238
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information



Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation

Budget Code Information

Mechanism ID: 18075			
Mechanism Name: Local Partners for Orphans & Vulnerable Children 2			
Prime Partner Name: Widows and Orphans Empowerment Organization			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,970,862	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	47,304
OVC_SERV_DSD	Age/Sex: 18+ Male	3,311



OVC_SERV_DSD	Age/Sex: 18+ Female	12,454
OVC_SERV_DSD	Sum of Age/Sex disaggregates	15,765
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	15,565
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	15,974

Implementing Mechanism Details

Mechanism ID: 18076	Mechanism Name: Global Health Program Cycle Improvement Project (GH Pro)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Dexis Consulting Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18076		
Mechanism Name:	Global Health Program Cycle Improvement Project (GH Pro)		
Prime Partner Name:	Dexis Consulting Group		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18127	Mechanism Name: Measure Evaluation IV
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,700,000	
Applied Pipeline Amount: 650,000	
Total All Funding Sources and Applied Pipeline Amount: 2,350,000	
Funding Source	Funding Amount
GHP-State	1,700,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18127



Mechanism Name:	Measure Evaluation IV		
Prime Partner Name:	University of North Carolina at Chapel Hill, Carolina Population Center		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	1,500,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18128	Mechanism Name: Coordinating Comprehensive Care for Children - 4 Children
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 3,284,144	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,284,144	
Funding Source	Funding Amount
GHP-State	3,284,144

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	200,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Economic Strengthening	160,000

Budget Code Information

Mechanism ID:	18128		
Mechanism Name:	Coordinating Comprehensive Care for Children - 4 Children		
Prime Partner Name:	Catholic Relief Services		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	3,284,144	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18129	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18438	Mechanism Name: Strengthening Applied Epidemiology and sustainable international public health capacity through FETP_1619
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: AFENET CDC HQ	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 2,500,000	
Total All Funding Sources and Applied Pipeline Amount: 2,500,000	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18438
----------------------	--------------



Mechanism Name: Strengthening Applied Epidemiology and sustainable international public health capacity through FETP_1619			
Prime Partner Name: AFENET CDC HQ			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18439	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18441	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18442	Mechanism Name: Global Health Supply Chain Program
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 97,250,183	
Applied Pipeline Amount: 56,304,285	



Total All Funding Sources and Applied Pipeline Amount: 153,554,468	
Funding Source	Funding Amount
GHP-State	97,250,183

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18442			
Mechanism Name: Global Health Supply Chain Program			
Prime Partner Name: Global Health Supply Chain Program			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,763,461	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	786,379	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	1,490,829	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	2,596,332	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	424,023	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	153,631	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	3,893,546	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	3,253,791	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	9,617,849	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	58,604,982	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	14,054,108	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	611,252	0

Implementing Mechanism Indicator Information

(No data provided.)

**Agency Information - Costs of Doing Business
U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		176,755		260,775	176,755	437,530



ICASS		1,093,835		620,703	1,093,835	1,714,538
Institutional Contractors		2,863,682		1,309,329	2,863,682	4,173,011
Management Meetings/Professional Development		238,535		209,524	238,535	448,059
Non-ICASS Administrative Costs		158,891		0	158,891	158,891
Staff Program Travel		124,475		442,050	124,475	566,525
USG Staff Salaries and Benefits - Internationally Recruited		1,931,561		507,844	1,931,561	2,439,405
USG Staff Salaries and Benefits - Locally Recruited		2,658,273		701,309	2,658,273	3,359,582
Total	0	9,246,007	0	4,051,534	9,246,007	13,297,541

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
-------------------------------	-----	-----------	-----------	------------------	-------	---



Computers/IT Services		38,833		30,582	38,833	69,415
ICASS		759,434		598,072	759,434	1,357,506
Indirect Costs		441,728		347,871	441,728	789,599
Non-ICASS Administrative Costs		305,271		240,408	305,271	545,679
Staff Program Travel		356,135		280,465	356,135	636,600
USG Staff Salaries and Benefits - Internationally Recruited		313,161		246,622	313,161	559,783
USG Staff Salaries and Benefits - Locally Recruited		825,566		650,153	825,566	1,475,719
Total	0	3,040,128	0	2,394,173	3,040,128	5,434,301

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing		0		1,624,686	0	1,624,686



Computers/IT Services		0		691,045	0	691,045
ICASS		0		2,090,926	0	2,090,926
Institutional Contractors				58,610	0	58,610
Management Meetings/Professional Development		0		363,835	0	363,835
Non-ICASS Administrative Costs		0		1,053,456	0	1,053,456
Non-ICASS Motor Vehicles		0		300,000	0	300,000
Staff Program Travel				906,165	0	906,165
USG Staff Salaries and Benefits - Internationally Recruited	1,354,550			0	1,354,550	1,354,550
USG Staff Salaries and Benefits - Locally Recruited	607,950	0		3,948,777	607,950	4,556,727
Total	1,962,500	0	0	11,037,500	1,962,500	13,000,000

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business
-------------------------------	-----	-----------	-----------	------------------	-------	----------------------------------

Approved



						Categories and Applied Pipeline Amount
ICASS		90,541		0	90,541	90,541
Non-ICASS Administrative Costs		5,000		0	5,000	5,000
Staff Program Travel		100,000		0	100,000	100,000
USG Staff Salaries and Benefits - Locally Recruited		524,000		0	524,000	524,000
Total	0	719,541	0	0	719,541	719,541